MARKET

CLDX

CLDX

Celldex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.730
+0.080
+4.85%
After Hours: 1.980 +0.25 +14.45% 18:35 04/03 EDT
OPEN
1.780
PREV CLOSE
1.650
HIGH
1.850
LOW
1.690
VOLUME
508.98K
TURNOVER
--
52 WEEK HIGH
5.47
52 WEEK LOW
1.500
MARKET CAP
30.40M
P/E (TTM)
-0.4769
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLDX stock price target is 12.00 with a high estimate of 16.00 and a low estimate of 8.00.

EPS

CLDX News

More
  • Celldex EPS beats by $0.29, beats on revenue
  • seekingalpha · 03/27 01:05
  • Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results
  • GlobeNewswire · 03/26 21:01
  • Celldex Therapeutics Reports $1.7M Milestone Payment From Rockefeller University Related To Collaboration On HIV Antibody Program
  • Benzinga · 03/03 13:25
  • Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program
  • GlobeNewswire · 03/03 13:01

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About CLDX

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.
More

Webull offers kinds of Celldex Therapeutics, Inc. stock information, including NASDAQ:CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions.